Disallowed

After this pull back from recent highs post FDA approval I believe there is a real chance this could become a Disallowed from this price. To recap what some insightful posters have mentioned already:

1. Market Cap is ridiculously cheap for a company that has a potential monopoly with APAS in a market worth upwards of $10Billion worldwide. MC currently a measly $57mil compare to other bio tech stocks in excess of $300mil with no FDA approval.

2. Share register is tight 115mil shares on issue means when it runs it runs hard. The inverse is also true so hold tight it will be a bumpy ride.

3. Its hard to determine Potential revenue but when looking at the potential market in which APAS will be marketed to ($10bil) even a modest chunk of that market share would see revenues in excess of LBTs current market cap.

4. Microstreak and Woundvue two other products that LBT has to roll out. While Microstreak is not currenly licensed to anyone LBT are seeking a new licensing partner for Microstreak which to date has already generated $21mil via the previous licensing partner.

Currently risks I see are the inevitable Capital raising as cash flow from Microsteak is on hold until a new licensing partner is signed. However with such a small share register LBTs share price should be able to absorb this. This Capital can then be used to keep the company running until APAS is rolled out in late 2017.

The other main concern pointed out by @funiture is the possibility of a takeover as the company is currently valued so low it would be very easy for a global bio giant to sweep LBT up in a blink.

All that aside I personal feel LBT has the potential over the coming years to be a Disallowed bringing the share price to roughly $5 with a Market cap somewhere between $500 - $700. It might even be worth more as the revenue of APAS, Microstreak and Woundvue combined is a little hard to determine at present. But even at that valuation it would still be on par with some of the hype that is out there now.

GLTAH